The role of pramipexole in a severe Parkinson's disease model in mice

scientific article

The role of pramipexole in a severe Parkinson's disease model in mice is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1177/1756285610389655
P932PMC publication ID3002641
P698PubMed publication ID21179594
P5875ResearchGate publication ID49703574

P2093author name stringMohamed Salama
Abdel Aziz Ghanem
Dina Eltantawy
Hasan Abdelghaffar
Sahar Eldakroury
Sara Eldosouky
Seham Gad Elhak
P2860cites workDopamine receptor activation promotes adult neurogenesis in an acute Parkinson modelQ28579481
A highly reproducible rotenone model of Parkinson's diseaseQ30490799
On the decline and etiology of high-incidence motor system disease in West Papua (southwest New Guinea).Q33221450
Animal models of PD: pieces of the same puzzle?Q33337447
Disease model: Parkinson's disease.Q35203031
Evaluation of animal models of Parkinson's disease for neuroprotective strategiesQ35920006
Factors involved in the determination of the neurotransmitter phenotype of developing neurons of the CNS: applications in cell replacement treatment for Parkinson's diseaseQ36300240
Animal models of Parkinson's disease and L-dopa induced dyskinesia: how close are we to the clinic?Q36953255
Neuronal cell replacement in Parkinson's disease.Q37599931
Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice.Q39818078
Neurotoxicity of MPTP to migrating neuroblasts: studies in acute and subacute mouse models of Parkinson's diseaseQ44427818
Treatment effects on nigrostriatal projection integrity in partial 6-OHDA lesions: comparison of L-DOPA and pramipexoleQ44574710
Moderate degeneration of nigral neurons after repeated but not after single intrastriatal injections of low doses of 6-hydroxydopamine in miceQ46884756
The effects of L-3,4-dihydroxyphenylalanine and dopamine agonists on dopamine neurons in the progressive hemiparkinsonian rat modelsQ48164714
Neuroprotection in Parkinson models varies with toxin administration protocolQ48343782
Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neuronsQ48831389
The potentiating effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on paraquat-induced neurochemical and behavioral changes in miceQ83035383
P433issue6
P921main subjectParkinson's diseaseQ11085
P304page(s)333-337
P577publication date2010-11-01
P1433published inTherapeutic advances in neurological disordersQ26842039
P1476titleThe role of pramipexole in a severe Parkinson's disease model in mice
P478volume3

Reverse relations

cites work (P2860)
Q42487975Pramipexole, a Dopamine D2/D3 Receptor-Preferring Agonist, Prevents Experimental Autoimmune Encephalomyelitis Development in Mice.
Q38231222The benefits of pramipexole selection in the treatment of Parkinson's disease.

Search more.